An international research team including scientists from the University of Toronto's Faculty of Medicine has discovered a link between a mutation in an immune system gene and Alzheimer's disease. Using data from 25,000 people, researchers from the Faculty of Medicine and University College...
Sanford-Burnham researchers discovered that the protein appoptosin prompts neurons to commit suicide in several neurological conditions - giving them a new therapeutic target for Alzheimer's disease and traumatic brain injury. Dying neurons lead to cognitive impairment and memory loss in...
New research from the US suggests that use of hormone therapy may affect women's risk for developing Alzheimer's disease: those who start it within five years of menopause may experience a lower risk, and those who start it later may experience a raised risk for the neurodegenerative disease...
A compound that was supposed to repair brain damage has become a promising medication for improving cognitive function in Alzheimer's disease, Washington State University researchers reported in the Journal of Pharmacology and Experimental Therapeutics. The scientists found that rats with...
Professional football players are much more likely to die from Alzheimer's disease, ALS (Lou Gerhig's disease) and other conditions cause by brain-cell damage, researchers from the National Institute for Occupational Safety and Health in Cincinnati wrote in the journal Neurology. The scientists...
It is estimated that 35 million people worldwide, including 5.4 million Americans have Alzheimer's disease. These figures are predicted to triple in one generation and the financial burden in the U.S. alone is around $200 billion dollars. A successful clinical Harvard trial now promises new hope...
According to a study published online in the Proceedings of the National Academy of Sciences, an FDA-approved anti-epileptic drug has been found to reverse memory loss in a mouse model of Alzheimer's disease . The study, conducted by researchers at the Gladstone Institutes, also found that the...
The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN). The current therapeutic market is valued at $3 to $4 billion...
The presence of specific autoantibodies of the immune system is associated with blood vessel damage in the brain. These findings were made by Marion Bimmler, a graduate engineer of medical laboratory diagnostics at the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch and Dr. Peter...
New investigational molecule discovered and developed collaboratively in the UK and Japan by Eisai Eisai in Europe today releases the first clinical data for E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor, presented during oral sessions at the Alzheimer's...
A "one-size-fits-all" new class of drugs that targets a particular type of brain inflammation is showing early promise for the treatment of Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury. A pre-clinical study due to be published this week in the...
Activity lingers longer in certain areas of the brain in those with Alzheimer's than it does in healthy people, Mayo Clinic researchers who created a map of the brain found. The results suggest varying brain activity may reduce the risk of Alzheimer's disease. The study, "Non-stationarity in the...
Genetic tests exist to identify risk for the rare inherited form of early-onset Alzheimer's disease (AD) and to predict susceptibility to the more common, late-onset form of AD, but do people want to know, and how do they react? The answers can be found in the article published in Genetic...
Rhode Island Hospital researcher Suzanne de la Monte, M.D., has found a link between brain insulin resistance (diabetes) and two other key mediators of neuronal injury that help Alzheimer's disease (AD) to propagate. The research found that once AD is established, therapeutic efforts must also...
An arsenal of Alzheimer's research revealed at the Society of Nuclear Medicine's 59th Annual Meeting indicates that beta-amyloid plaque in the brain not only is involved in the pathology of Alzheimer's disease but may also precede even mild cognitive decline. These and other studies advance...
If you can't walk into a store without buying something, help may be at hand. New research suggests that a drug designed to treat Alzheimer's disease can be used to successfully treat people who suffer from shopping addictions. More »
Alzheimer's disease (AD) is a major neurodegenerative disorder that affects millions of people worldwide. New and accurate techniques for early diagnosis are critical. Pravat K. Mandal, PhD, and his colleagues have developed a completely non-invasive brain imaging technique to measure specific...
A drug prescribed for Alzheimer's disease does not ease clinically significant agitation in patients, according to a new study conducted by researchers from the U.K., U.S. and Norway. This is the first randomized controlled trial designed to assess the effectiveness of the drug (generic name...
Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal...